Nucleotide excision repair is a predictor of early relapse in pediatric acute lymphoblastic leukemia.

Authors:
Omar M Ibrahim
Omar M Ibrahim
School of Pharmacy
United States
Stephen G Grant
Stephen G Grant
Graduate School of Public Health
United States
Dr. Jean J Latimer, Ph.D.
Dr. Jean J Latimer, Ph.D.
Nova Southeastern University AutoNation Cancer Institute
Director, AutoNation Institute for Breast Cancer
Breast cancer
Fort Lauderdale, Florida | United States

BMC Med Genomics 2018 Oct 30;11(1):95. Epub 2018 Oct 30.

Department of Pharmaceutical Sciences, College of Pharmacy, 3200 S University Drive, Fort Lauderdale, FL, 33328, USA.

Background: Nucleotide Excision Repair (NER) is a major pathway of mammalian DNA repair that is associated with drug resistance and has not been well characterized in acute lymphoblastic leukemia (ALL). The objective of this study was to explore the role of NER in relapsed ALL patients. We hypothesized that increased expression of NER genes was associated with drug resistance and relapse in ALL.

Methods: We performed secondary data analysis on two sets of pediatric ALL patients that all ultimately relapsed, and who had matched diagnosis-relapse gene expression microarray data (GSE28460 and GSE18497). GSE28460 included 49 precursor-B-ALL patients, and GSE18497 included 27 precursor-B-ALL and 14 T-ALL patients. Microarray data were processed using the Plier 16 algorithm and the 20 canonical NER genes were extracted. Comparisons were made between time of diagnosis and relapse, and between early and late relapsing subgroups. The Chi-square test was used to evaluate whether NER gene expression was altered at the level of the entire pathway and individual gene expression was compared using t-tests.

Results: We found that gene expression of the NER pathway was significantly increased upon relapse in patients that took 3 years or greater to relapse (late relapsers, P?=?.007), whereas no such change was evident in patients that relapsed in less than 3 years (early relapsers, P?= .180). Moreover, at diagnosis, the NER gene expression of the early relapsing subpopulation was already significantly elevated over that of the late relapsing group (P?
Conclusion: Patients are over two times more likely to undergo early relapse if they have a high NER score at diagnosis, hazard ratio 2.008, 95% CI (1.256-3.211). The NER score may provide a underlying mechanism for "time to remission", a known prognostic factor in ALL, and a rationale for differential treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-018-0422-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208034PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
October 2018
229 Reads
1 Citation
3.000 Impact Factor

Publication Analysis

Top Keywords

gene expression
20
drug resistance
8
late relapsing
8
associated drug
8
acute lymphoblastic
8
expression ner
8
ner genes
8
lymphoblastic leukemia
8
microarray data
8
included precursor-b-all
8
nucleotide excision
8
ner gene
8
excision repair
8
ner
7
expression
6
patients
6
gene
5
relapse
5
algorithm canonical
4
early late
4

Similar Publications